Rsvpref3 Antigen/As01e/Pf
Brand name: Arexvy
Rank #30 of 500 drugs by total cost
$608.6M
Total Cost
1,935,431
Total Claims
$608.6M
Total Cost
10,631
Prescribers
$314
Cost per Claim
1,933,590
Beneficiaries
1,936,732
30-Day Fills
$57K
Avg Cost/Provider
182
Avg Claims/Provider
About Rsvpref3 Antigen/As01e/Pf
Rsvpref3 Antigen/As01e/Pf (sold as Arexvy) was prescribed 1,935,431 times by 10,631 Medicare Part D providers in 2023, costing the program $608.6M. At $314 per claim, this is a moderately priced medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 27 | Linaclotide (Linzess) | $639.4M | 823,023 |
| 28 | Insulin Lispro (Humalog Kwikpen U-100) | $623.9M | 854,813 |
| 29 | Dupilumab (Dupixent Pen) | $609.1M | 156,267 |
| 30 | Rsvpref3 Antigen/As01e/Pf (Arexvy) | $608.6M | 1,935,431 |
| 31 | Pomalidomide (Pomalyst) | $589.0M | 27,253 |
| 32 | Lipase/Protease/Amylase (Zenpep) | $577.7M | 321,809 |
| 33 | Insulin Degludec (Tresiba Flextouch U-100) | $567.8M | 597,178 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology